338 related articles for article (PubMed ID: 19906293)
1. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
2. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.
Gladue RP; Paradis T; Cole SH; Donovan C; Nelson R; Alpert R; Gardner J; Natoli E; Elliott E; Shepard R; Bedian V
Cancer Immunol Immunother; 2011 Jul; 60(7):1009-17. PubMed ID: 21479995
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.
Krug A; Towarowski A; Britsch S; Rothenfusser S; Hornung V; Bals R; Giese T; Engelmann H; Endres S; Krieg AM; Hartmann G
Eur J Immunol; 2001 Oct; 31(10):3026-37. PubMed ID: 11592079
[TBL] [Abstract][Full Text] [Related]
4. Comparison of human B cell activation by TLR7 and TLR9 agonists.
Hanten JA; Vasilakos JP; Riter CL; Neys L; Lipson KE; Alkan SS; Birmachu W
BMC Immunol; 2008 Jul; 9():39. PubMed ID: 18652679
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
6. B cell TLR1/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses.
Pone EJ; Lou Z; Lam T; Greenberg ML; Wang R; Xu Z; Casali P
Autoimmunity; 2015 Feb; 48(1):1-12. PubMed ID: 25536171
[TBL] [Abstract][Full Text] [Related]
7. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
9. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
10. CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells.
Mathieu M; Cotta-Grand N; Daudelin JF; Boulet S; Lapointe R; Labrecque N
PLoS One; 2012; 7(1):e30139. PubMed ID: 22291907
[TBL] [Abstract][Full Text] [Related]
11. Induction of dendritic cell costimulator molecule expression is suppressed by T cells in the absence of antigen-specific signalling: role of cluster formation, CD40 and HLA-class II for dendritic cell activation.
McLellan AD; Heiser A; Hart DN
Immunology; 1999 Oct; 98(2):171-80. PubMed ID: 10540215
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation.
Ozcan E; Rauter I; Garibyan L; Dillon SR; Geha RS
J Allergy Clin Immunol; 2011 Sep; 128(3):601-9.e1-4. PubMed ID: 21741080
[TBL] [Abstract][Full Text] [Related]
13. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.
Wagner M; Poeck H; Jahrsdoerfer B; Rothenfusser S; Prell D; Bohle B; Tuma E; Giese T; Ellwart JW; Endres S; Hartmann G
J Immunol; 2004 Jan; 172(2):954-63. PubMed ID: 14707068
[TBL] [Abstract][Full Text] [Related]
14. CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.
Puliaev R; Puliaeva I; Welniak LA; Ryan AE; Haas M; Murphy WJ; Via CS
J Immunol; 2008 Jul; 181(1):47-61. PubMed ID: 18566369
[TBL] [Abstract][Full Text] [Related]
15. TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function.
Jiang W; Lederman MM; Harding CV; Rodriguez B; Mohner RJ; Sieg SF
Eur J Immunol; 2007 Aug; 37(8):2205-13. PubMed ID: 17621369
[TBL] [Abstract][Full Text] [Related]
16. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.
Buhtoiarov IN; Lum HD; Berke G; Sondel PM; Rakhmilevich AL
J Immunol; 2006 Jan; 176(1):309-18. PubMed ID: 16365423
[TBL] [Abstract][Full Text] [Related]
18. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production.
Giordani L; Sanchez M; Libri I; Quaranta MG; Mattioli B; Viora M
J Leukoc Biol; 2009 Aug; 86(2):261-71. PubMed ID: 19401392
[TBL] [Abstract][Full Text] [Related]
19. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.
Shimabukuro-Vornhagen A; Draube A; Liebig TM; Rothe A; Kochanek M; von Bergwelt-Baildon MS
J Exp Clin Cancer Res; 2012 May; 31(1):47. PubMed ID: 22592077
[TBL] [Abstract][Full Text] [Related]
20. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
